Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
12.05
+0.07 (0.58%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Palvella Therapeutics, Inc. develops and commercializes pathogenetically targeted therapies to treat patients suffering from serious and rare genetic skin diseases for which there are no FDA-approved therapies.
It develops QTORIN, a patented platform that designs to generate new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases.
The company was incorporated in 2015 and is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| CEO | Wesley Kaupinen |
Contact Details
Address: 125 Strafford Avenue, Suite #360 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 253 1460 |
| Website | palvellatx.com |
Stock Details
| Ticker Symbol | PVLA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001742961 |
Key Executives
| Name | Position |
|---|---|
| Wesley Kaupinen | Chief Executive Officer |
| Matthew Korenberg | Chief Financial Officer |
| Kathy Goin | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2022 | D | Notice of Exempt Offering of Securities |
| Jun 3, 2020 | D | Notice of Exempt Offering of Securities |
| Aug 12, 2019 | D/A | Filing |
| Apr 12, 2019 | D | Notice of Exempt Offering of Securities |
| Jun 14, 2018 | D | Notice of Exempt Offering of Securities |